Opinion: Bad medicine: aducanumab is a lackluster drug with a high price tag
Controversy has swirled around aducanumab, an experimental drug developed by Biogen, long before the FDA approved it on Monday to treat early-stage Alzheimer’s disease. The agency now finds itself under scrutiny in a situation with no good outcome.
There were defensible arguments for approval, one of which is that until now there has been no disease-altering therapy to offer to individuals with Alzheimer’s or their families.
